DIVI'S LABORATORIES LIMITED

Consensus Divi's Laboratories Limited

Stocks

DIVISLAB

INE361B01024

Pharmaceuticals

Delayed NSE India S.E. 12:05:08 15/09/2026 BST			5-day change	1st Jan Change
9,198.00 ^INR	-1.33%		-3.94%	+43.89%

08-01	Divi's Laboratories Limited, Q1 2027 Earnings Call, Aug 01, 2026
08-01	Divi's Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026	CI

Evolution of the Average Target: Divi's Laboratories Limited

Evolution of the Target Price: Divi's Laboratories Limited

Changes in Analyst Recommendations: Divi's Laboratories Limited

50e3790a9eba2b7269.sW05a65TlsmeRAju2nnc64Yxr37QVUauUz138Xrsz9I.xy91RugG77noEleiuQ62iPxy7VO7LC_mKQUZnQuzroP_OmoG6AfGpfMQOA~ee5cd1ced39e08e04d32b734ddce09aa

Analysts' recommendations: Divi's Laboratories Limited

05-25	Choice Equity Upgrades Divi's Laboratories to Add from Reduce; Price Target is INR7,375	MT
05-25	Jefferies Adjusts Divi's Laboratories' Price Target to INR7,950 from INR8,100, Keeps at Buy	MT
04-01	Avendus Spark Upgrades Divi's Laboratories to Reduce from Sell, Price Target is INR5,840	MT
02-12	Jefferies Adjusts Divi's Laboratories' Price Target to INR8,100 From INR8,000, Keeps at Buy	MT
11-10	Jefferies Adjusts Divi's Laboratories' Price Target to INR7,850 From INR7,150, Keeps at Buy	MT
07/08/25	Jefferies Adjusts Divi's Laboratories' Price Target to INR6,750 From INR6,200, Keeps at Hold	MT
19/05/25	Jefferies Adjusts Divi's Laboratories' Price Target to INR6,200 From INR6,280, Keeps at Hold	MT
11/11/24	Jefferies Adjusts Divi's Laboratories' Price Target to INR5,790 From INR4,830, Keeps at Hold	MT
05/08/24	Jefferies Adjusts Divi's Laboratories' Price Target to INR4,830 From INR4,050, Keeps at Hold	MT
27/05/24	Jefferies Adjusts Divi’s Laboratories Price Target to INR4,050 From INR3,610, Keeps at Hold	MT
07/11/23	Jefferies Downgrades Divi’s Laboratories to Hold From Buy, Adjusts Price Target to INR3,510 From INR4,300	MT
15/08/23	Jefferies Adjusts Divi’s Laboratories’ Price Target to INR4,300 From INR3,610, Keeps at Buy	MT
22/05/23	Jefferies Upgrades Divi’s Laboratories to Buy From Underperform, Adjusts Price Target to INR3,610 From INR 2,550	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	DIVI'S LABORATORIES LIMITED					-9.39%
	ELI LILLY AND COMPANY					+15.85%
	JOHNSON & JOHNSON					+4.35%
	ABBVIE INC.					+6.43%
	ROCHE HOLDING AG					+3.41%
	NOVARTIS AG					+10.07%
	ASTRAZENECA PLC					+29.47%
	AMGEN INC.					+1.71%
	NOVO NORDISK A/S					+10.62%
	GILEAD SCIENCES, INC.					+8.02%
	Average					+8.05%
	Weighted average by Cap.					+10.23%

See all sector performances

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

OUTPERFORM

Number of Analysts

29

Last Close Price

9,198.00INR

Average target price

8,447.00INR

Spread / Average Target

-8.16%

High Price Target

11,700.00INR

Spread / Highest target

+27.20%

Low Price Target

6,000.00INR

Spread / Lowest Target

-34.77%

Analyst Consensus Detail

Consensus revision (last 18 months)

Ratings

Trader

Investor

Global

Quality

ESG MSCI

BB

Stock Market
Stocks
DIVISLAB Stock
Consensus Divi's Laboratories Limited

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!

SEIZE THE OFFER!